Literature DB >> 8960824

Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats.

P Odetti1, N Traverso, L Cosso, G Noberasco, M A Pronzato, U M Marinari.   

Abstract

Blood glucose control plays a prominent role in the aetiology of diabetic complications. Recent data support the hypothesis that non-enzymatic pathways (glycation and oxidation) are involved in the pathogenesis of tissue damage in diabetes mellitus. In this study the level of pentosidine, a marker of glycation, and the intensity of collagen-linked fluorescence glycation (370/440 and 335/385 nm) and oxidation-related (356/460 and 390/460 nm), have been examined in spontaneously diabetic rats with good and poor glycaemic control. Pentosidine increased dramatically in rats with poor control, and slightly in those with good control. At the end of the study, after 6 months of diabetes, pentosidine levels were 13 +/- 5 and 2.1 +/- 0.5 pmol/mg collagen, respectively (control rats: 1.1 +/- 0.1 pmol/mg collagen). A similar pattern was observed for both glycation or oxidation-related fluorescence. The group of rats with poor control always showed elevated average values when compared to rats with good control, with a relative increase of over 200%. The results emphasize the role of good glycaemic control in preventing the growth of glycation or oxidation end-products in collagen. On comparison between the general mean level of all glycated haemoglobin and the mean pentosidine level of the three groups, a very good exponential correlation was found (r = 0.993, p < 0.001). The fluorescence values presented a less strong relationship, but a correlation with glycaemic control was still present. If the post-translational modifications of proteins play a leading role in the pathogenesis of complications it is possible to conclude that strict glycaemic control, obtained by accurate insulin therapy can prevent them by inhibiting the non-enzymatic modification of proteins and delaying their accumulation in collagen. The therapeutic implications are obvious.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960824     DOI: 10.1007/s001250050596

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  5 in total

1.  Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

Authors:  B H Wolffenbuttel; C M Boulanger; F R Crijns; M S Huijberts; P Poitevin; G N Swennen; S Vasan; J J Egan; P Ulrich; A Cerami; B I Lévy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

2.  Aminoguanidine prevents impaired healing and deficient angiogenesis in diabetic rats.

Authors:  A S Teixeira; M V Caliari; O A Rocha; R D Machado; S P Andrade
Journal:  Inflammation       Date:  1999-12       Impact factor: 4.092

Review 3.  Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

4.  Age-dependent accumulation of advanced glycation endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine.

Authors:  A Georgescu; D Popov
Journal:  J Am Aging Assoc       Date:  2000-01

5.  An advanced glycation endproduct (AGE)-rich diet promotes accumulation of AGEs in Achilles tendon.

Authors:  Dorthe Skovgaard; Rene B Svensson; Jean Scheijen; Pernilla Eliasson; Pernille Mogensen; Anne Mette F Hag; Michael Kjær; Casper G Schalkwijk; Peter Schjerling; Stig P Magnusson; Christian Couppé
Journal:  Physiol Rep       Date:  2017-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.